Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
What Is The Price Target For Fate Therapeutics Fate Stock Fate Q4 2025 Earnings Fate Therapeutics Inc. Posts Narrow Eps Beat No Revenue Reported 20260410 1 Can Yimutian Ymt Stock Recover Now Price At 0.21 Up 0.14 20260410 Is Amalgamated Amal Stock A Market Leader Price At 39.91 Up 1.31 20260406 Is Northern Ntic Stock Good For Active Traders Price At 8.06 Down 0.49 20260408 Will Primis Financial Frst Stock Hit Record Highs Price At 14.19 Up 1.14 20260409 What Aclarion ACON is doing that smart money tracks Momentum Building 20260508 The strategic moves Lumexa LMRI is making now Weakens 20260507 HDSN Hudson Technologies Inc Q4 2025 EPS misses sharply stock edges lower even as revenue rises 4 percent year over year How LivaNova PLC LIVN management quality shows in execution Q1 2026 Profit Surprises Unicycive Therapeutics UNCY Stock Is It Worth Allocating Capital Q4 2025 EPS Misses Estimates Market Wrap Tech leads sector gains consumer lags as major indexes dip modestly Our Bond OBAI Peer Comparison Earnings Report Occidental Petroleum Corporation OXY Analyst Target Upgrades Gulf of America Discovery Support Bullish NearTerm Outlook RTX Corporation RTX Pratt Whitney Commits 100M Polish Capacity Expansion to Address Rising Commercial and Military Engine Demand Why Graco GGG business model holds up in any market 214 20260506 What resistance level for LXP LXP Smart Money Exits 20260429 HRZN Horizon stock jumps 744 even after Q4 2025 pershare earnings miss analyst projections by a wide margin What Ares Capital ARCC does better than 90 of companies Selling Pressure 20260508 The opportunity most miss about Aptevo APVO Selling Pressure 20260508 Inflation Concerns Resurface What It Means for Markets in May 2026 Bill Ackman Quietly Accumulated Microsoft Shares Since February Amid AI Selloff Betting on Azure and Massive Capex Amazon Meta and Microsoft Face Growing Public Backlash Over AI Data Center Expansion CN Corp CZNC Down 241 How Low Could It Go 20260515 Privia PRVA Slips 095 Testing 2187 Support 20260515 Reddit RDDT Slips 210 Testing 14799 Support 20260519 Kandal M FMFC Falls 162 Watching 039 Support 20260515 WSFS WSFS Climbs 060 Resistance at 7383 in Focus 20260518 Western WRN Q1 2026 Earnings Soft Quarter Raises Questions Carnival CCL Q1 2026 Earnings Why the Beat Matters Montero Mining Initiates Drill Program at Elvira Project Advancing Exploration Efforts Why Coca Cola KOF Just Surged 131 Key Levels Ahead 20260520 BitMine Emerges as Candidate for Russell 1000 Index Inclusion Burberry Shares Rise on Moncler Takeover Speculation JM Smucker SJM Faces Headwinds as JPMorgan Reduces Price Target and Forward Estimates Tax Implications of NPS Tier II Equity Fund Withdrawals ShortTerm vs LongTerm Capital Gains Consumer Sentiment Drops to Record Low in May on Surging Gas Prices Amid Iran Conflict Outset Medical Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Reaction ANNX Q1 2026 Earnings Clinical Pipeline Progress Drives EPS Beat as Stock Dips on Broader Biotech Headwinds SCZM Q1 2026 Earnings EPS Misses Estimates as Revenue Details Remain Undisclosed BancFirst Corporation BANF Q1 2026 Earnings Solid EPS Beat Lifts Banks Start to Fiscal Year Cineverse Corp CNVS Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Surprise Despite Revenue Challenges Roku Inc ROKU Holds Steady Near Support Is a Breakout Imminent Marathon Petroleum MPC Pushes Higher Testing Key Levels After 25 Gain Bleichroeder Acquisition Corp II BBCQ Edges Higher SPAC Stock Shows Modest Uptick GameStop GME Pulls Back Support Levels Under Scrutiny After 236 Decline How New NPACW compares to the market average 333 20260508 CRAC CrownReserve quarterly earnings details are still pending leadership will lay out core strategic priorities at next weeks investor call Why ParaZero Technologies PRZO deserves more attention from serious investors Mini Selloff 20260506 Costamare CMRE Risk Reward Ratio Q4 2025 Below Expectations GOSS Gossamer Bio shares rise 521 percent even as Q4 2025 EPS narrowly misses analyst expectations